To help celebrate World Hemophilia Day, pharma giant Grifols announced that it will donate 140 million international units (IU) of Factor VIII to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over the next 5 years.
The donations will help children with hemophilia A in developing countries get access the medicine they need. The donations should dramatically change many children’s lives. Theoretically, the donations amounts to 10,300 doses to treat approximately 6,000 patients per year in developing countries worldwide through 2021, where access to adequate treatment is often lacking or absent.
Grifols’ drug, Alphanate (antihemophilic factor/von Willebrand factor complex) is approved for hemophilia A and von Willebrand disease.
In a news release, Victor Grifols Roura, President of Grifols said,"Today, World Hemophilia Day represents ideal timing for Grifols to reaffirm our long-standing commitment to bleeding disorders and the hemophilia community." Grifols Roura added, "Our philosophy aligns fully with the mission of WFH, sharing a clear passion for providing adequate treatment for all patients regardless of where they live."
According to the WFH, only 25% of hemophilia patients in the world receive adequate treatment.
Hemophilia A results in impaired clotting mechanisms due to missing or reduced levels of factor VIII. People with hemophilia A experience recurrent and extended bleeding episodes that cause pain and irreversible joint damage. Some of these bleeding episodes can be life threatening. There are an estimated 16,000 – 20,000 people in the United States with hemophilia A (and 142,000 world wide).